Figure 1.
FEV1% predicted values during the 12-month follow-up period in each cluster (adapted from Kim TB et al., Eur Respir J, 2013;41:1308–1314.).
Table 1.
FEV1% predicted valuesduring the 12-month follow-up period in each cluster.
Figure 2.
ACT scores during the 12-month follow-up period in each cluster.
Table 2.
ACT scores during the 12-month follow-up period in each cluster.
Figure 3.
Percentage of use of systemic corticosteroids during the 12-month follow-up period in each cluster.
Table 3.
Percentage of use of systemic corticosteroids during the 12-month follow-up period in each cluster.
Figure 4.
QLQAKA scores during the 12-month follow-up period in each cluster.
Table 4.
QLQAKA scores during the 12-month follow-up period in each cluster.